TMO logo

THERMO FISHER SCIENTIFIC INC

TMONYSE
πŸ† #53 by market capEarnings Jan 27 Β· PostUS Equity
$704.15β–² $11.16 (+1.61%)
πŸŒ™ After hours$706.50β–² 0.33%Regular close Β· extended-hours price shown
πŸ””
Track TMO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.6%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$260.36B
Large Cap
πŸ“ˆRevenue Growth (YoY)
8.3%
Slowing
πŸ“ŠGross Margin
41.2%
Healthy
πŸ’΅FCF Margin
16.0%
Healthy
βš–οΈP/S Ratio
5.3x
Fair
Otter Score
72
Strong
No chart data available for TMO.

Trading Snapshot

Day Range
$691.03 – $710.84
52-Week Range
$435.27 – $705.79
Volume (shares)
1,647,700
Avg Volume (shares)
β€”
Shares Outstanding
369.8M
Next Earnings
2027-01-27

Fundamentals Snapshot

Annual Revenue
$44.56B
Last Q Revenue
$12.14B
P/E Ratio
35.6
P/S Ratio
5.3x
EPS (TTM)
$18.94
Dividend Yield
0.27%
Dilution (1yr)
βˆ’1.6%
TMO logo

THERMO FISHER SCIENTIFIC INC

TMO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$44.6Bβ–² +3.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
40.9%β–Ό βˆ’1.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$8.1Bβ–² +5.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$6.3Bβ–Ό βˆ’13.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
377.0Mβ–Ό βˆ’1.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$29.5Bβ–Ό βˆ’$767M YoY
StockOtter Β· stockotter.space

About THERMO FISHER SCIENTIFIC INC

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100

Analyst Ratings

β“˜
Consensus
Buy
35 analysts
Strong Buy11
Buy19
Hold5
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Seeking AlphaΒ·1d ago

Parnassus Value Equity Fund Q3 2026 Portfolio Review

Parnassus Value Equity Fund (Investor Shares) returned -1.38% (net of fees) for the quarter, underperforming the Russell 1000 Value Index's 2.61%. Top contributors include Thermo Fisher, CME Group, NICE, Willis Towers Wa

GuruFocusΒ·2d ago

Is TMO Overvalued? DCF Says Worth $352

On October 26, 2026, we conducted a DCF analysis for Thermo Fisher Scientific Inc (TMO), a company currently trading at $673.82. The stock has shown a year-to-d

Seeking AlphaΒ·2d ago

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guid

247 WallstΒ·5d ago

Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More

A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of the week's most clo

Seeking AlphaΒ·7d ago

Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore

Thermo Fisher Scientific Inc. delivered strong Q3 results, with 6% organic growth, EPS and sales beats, and raised full-year guidance. TMO's growth is driven by robust demand in clinical research, bioproduction, and elec

The Motley FoolΒ·7d ago

Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors

Thermo Fisher raised its 2026 organic revenue growth outlook to 4%. Third-quarter revenue reached $12.14 billion with 6% organic growth.